导管原位癌的放射治疗
Radiotherapy of Ductal Carcinoma In Situ.
作者信息
Krug David, Souchon Rainer
机构信息
Radioonkologie und Strahlentherapie, Universitätsklinikum Heidelberg, Germany.
Formerly University Hospital Tübingen, Germany.
出版信息
Breast Care (Basel). 2015 Aug;10(4):259-64. doi: 10.1159/000437452. Epub 2015 Aug 19.
Abstract
Ductal carcinoma in situ (DCIS) is a heterogeneous disease in both its biology and clinical course. In the past, recurrence rates after breast-conserving surgery have been as high as 30% after 10 years. The introduction of mammography screening and advances in imaging have led to an increase in the detection of DCIS. The focus of this review is on the role of radiotherapy in the multidisciplinary treatment, including current developments in hypofractionation and boost delivery, and attempts to define low-risk subsets of DCIS for which the need for adjuvant radiation is repeatedly questioned.
摘要
导管原位癌（DCIS）在生物学特性和临床病程方面都是一种异质性疾病。过去，保乳手术后10年的复发率高达30%。乳腺钼靶筛查的引入以及影像学的进展导致DCIS的检出率有所增加。本综述的重点是放疗在多学科治疗中的作用，包括当前在大分割放疗和追加剂量放疗方面的进展，以及试图界定DCIS的低风险亚组，针对这些亚组，辅助放疗的必要性一直受到质疑。
相似文献
1
Radiotherapy of Ductal Carcinoma In Situ.
Breast Care (Basel). 2015 Aug;10(4):259-64. doi: 10.1159/000437452. Epub 2015 Aug 19.
2
Radiotherapy for ductal carcinoma in situ.
Clin Oncol (R Coll Radiol). 2006 Apr;18(3):179-84. doi: 10.1016/j.clon.2005.11.002.
3
Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ.
Cancer. 2011 Jan 1;117(1):54-62. doi: 10.1002/cncr.25344. Epub 2010 Aug 27.
4
Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy.
J Clin Oncol. 2007 Dec 10;25(35):5591-6. doi: 10.1200/JCO.2007.11.4686. Epub 2007 Nov 5.
5
[The treatment of ductal carcinoma in situ (DCIS) of the breast].
Ned Tijdschr Geneeskd. 2003 Nov 1;147(44):2157-61.
6
Current view on ductal carcinoma in situ and importance of the margin thresholds: A review.
Facts Views Vis Obgyn. 2014;6(4):210-8.
7
The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies.
Radiother Oncol. 2015 Jan;114(1):50-5. doi: 10.1016/j.radonc.2015.01.001. Epub 2015 Jan 14.
8
Recurrent cancer after breast-conserving surgery with radiation therapy for ductal carcinoma in situ: mammographic features, method of detection, and stage of recurrence.
AJR Am J Roentgenol. 2007 Jul;189(1):140-4. doi: 10.2214/AJR.06.1281.
9
Mammographic features of local recurrence in women who have undergone breast-conserving therapy for ductal carcinoma in situ.
AJR Am J Roentgenol. 1997 Feb;168(2):489-93. doi: 10.2214/ajr.168.2.9016233.
10
Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy.
Cancer. 2000 Feb 1;88(3):596-607. doi: 10.1002/(sici)1097-0142(20000201)88:3<596::aid-cncr16>3.0.co;2-n.
引用本文的文献
1
Scoping review: (Bio)markers for the prognostication of breast cancer recurrence.
BMC Cancer. 2025 Jul 1;25(1):1081. doi: 10.1186/s12885-025-14515-z.
2
Hypofractionation with concomitant boost using intensity-modulated radiation therapy in early-stage breast cancer in Mexico.
Rep Pract Oncol Radiother. 2018 Jul-Aug;23(4):276-283. doi: 10.1016/j.rpor.2018.06.006. Epub 2018 Jul 26.
3
[Optimal margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ : Results of the ASTRO, ASCO, and SSO consensus guideline].
Strahlenther Onkol. 2017 Oct;193(10):859-860. doi: 10.1007/s00066-017-1190-1.
4
Current controversies in radiotherapy for breast cancer.
Radiat Oncol. 2017 Jan 23;12(1):25. doi: 10.1186/s13014-017-0766-3.
5
[Omission of adjuvant radiotherapy in ductal carcinoma in situ : 12 year-results of the ECOG-ACRIN E5194-trial].
Strahlenther Onkol. 2016 May;192(5):349-51. doi: 10.1007/s00066-016-0966-z.
本文引用的文献
1
Molecular phenotypes of DCIS predict overall and invasive recurrence.
Ann Oncol. 2015 May;26(5):1019-1025. doi: 10.1093/annonc/mdv062. Epub 2015 Feb 12.
2
When is good enough really good enough? Defining the role of radiation in low-risk ductal carcinoma in situ.
J Clin Oncol. 2015 Mar 1;33(7):686-91. doi: 10.1200/JCO.2014.59.4259. Epub 2015 Jan 20.
3
RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.
J Clin Oncol. 2015 Mar 1;33(7):709-15. doi: 10.1200/JCO.2014.57.9029. Epub 2015 Jan 20.
4
Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Ann Oncol. 2015 Apr;26(4):682-687. doi: 10.1093/annonc/mdv013. Epub 2015 Jan 18.
5
The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies.
Radiother Oncol. 2015 Jan;114(1):50-5. doi: 10.1016/j.radonc.2015.01.001. Epub 2015 Jan 14.
6
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
Lancet Oncol. 2015 Jan;16(1):47-56. doi: 10.1016/S1470-2045(14)71156-8. Epub 2014 Dec 9.
7
Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013.
JAMA. 2014 Dec 17;312(23):2542-50. doi: 10.1001/jama.2014.16616.
8
Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial.
J Clin Oncol. 2014 Nov 10;32(32):3613-8. doi: 10.1200/JCO.2014.56.2595. Epub 2014 Oct 13.
9
Are the randomized trials of radiation therapy for ductal carcinoma in situ still relevant?
J Clin Oncol. 2014 Nov 10;32(32):3588-90. doi: 10.1200/JCO.2014.58.1066. Epub 2014 Oct 13.
10
Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast.
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1017-24. doi: 10.1016/j.ijrobp.2014.07.026. Epub 2014 Sep 11.
Zotero 插件